High urgency

Tom's of Maine toothpaste made with bacteria-contaminated water, says FDA - goodmorningamerica.com

Detected August 9, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

FDA reports that Tom's of Maine toothpaste was made with bacteria-contaminated water, indicating potential cGMP violations at the manufacturing facility.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 9, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Tom's of Maine and its parent company, as well as any contract manufacturers or suppliers involved in their production; also serves as a warning for all OTC drug and cosmetic manufacturers. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the provided text.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

FDA publicly disclosed that Tom's of Maine toothpaste was manufactured using water contaminated with bacteria, signaling a potential violation of current Good Manufacturing Practice (cGMP) regulations.

Who it affects

Tom's of Maine and its parent company, as well as any contract manufacturers or suppliers involved in their production; also serves as a warning for all OTC drug and cosmetic manufacturers.

What you must do

Manufacturers should review their water systems and cGMP compliance, and if they are Tom's of Maine, cooperate with FDA and initiate corrective actions.

Deadline

Not specified in the provided text.

Source: https://news.google.com/rss/articles/CBMitAFBVV95cUxOUkVEc2pPQi1Lald2OURnc3pWYmJwd1V4VUctbXphcjRlbHdfSnZOWV8xc1FaeThIbFB1c2NkaXozc0pNQWRzb0tyakxoWlVqamZ5Q1FPdXp4MW41c2JaVTJGaGlVVUwyajRwNkF4aWZlcGpyaDJueXNyYVZvWG9BYWtYTlhLYmhPOFRsM3d6dFRKbFhJNzdJaGdxM0kxdFVRWFZEanZGY0dtLW9RVWc2Z3JPdGjSAboBQVVfeXFMUHYtQldva05hMlZEeFFaaFVmb2Q3S1pjM19qX0l1ZHVYTHdXZG9temRHT19sejZuS1lDY1BnSExVOWwwSHV3U2RHS003dlNjalNEWjZiWEJDbE1GSkplLWpfUEltUm5CZUp1elhPanpha2NMcXE1OWotNXUxV2xRZjJBMDVmUGstUm4xMDROSXZjV2d4c0sxTktBXzNRRmNQdjVYbnlfQlNnaWM5NldfYW1Bb2owdFBPa3dR?oc=5

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)